Aoki, CA
Debora E. Aoki, Oakland, CA US
Patent application number | Description | Published |
---|---|---|
20100121649 | METHODS AND SYSTEMS FOR USER REGISTRATION - A method and a system to register a user include using some user information stored and provided by a third party system. For example, the user may provide an identifier associated with the third party system. The identifier may be used to retrieve the user information. The user information may be used to at least partially complete the user registration. | 05-13-2010 |
20140279616 | SYSTEM AND METHOD OF UTILIZING INFORMATION FROM A SOCIAL MEDIA SERVICE IN AN ECOMMERCE SERVICE - A system and method of utilizing information from a social media service in an ecommerce system are provided. Log-in information for a social media service of a user of an ecommerce service may be received. Then, information may be retrieved from the social media service using the log-in information. This information can then be used to alter a reputation rating for a user in the ecommerce system or to form a trading circle with other users of the ecommerce system. | 09-18-2014 |
Dion Aoki, Santa Monica, CA US
Patent application number | Description | Published |
---|---|---|
20160071359 | GAMING SYSTEM WITH PRIVACY FEATURES - A wagering game system includes a peripheral device with a peripheral device display and at least one processor configured to execute at least one application to display information on the peripheral device display. The system also includes a wagering game terminal with a terminal display configured to display a wagering game and a player-accessible interface configured to allow a player to communicatively couple the peripheral device to the wagering game terminal. The at least one application includes a wagering game application relating to the wagering game displayed on the terminal display of the wagering game terminal, and the at least one processor of the peripheral device executes the wagering application to display, on the peripheral device display, wagering game information relating to the wagering game. | 03-10-2016 |
Dion K. Aoki, Santa Monica, CA US
Patent application number | Description | Published |
---|---|---|
20150356824 | GAMING SYSTEM HAVING PASSIVE PLAYER PARTICIPATION IN SECONDARY WAGERING GAMES - A gaming system comprises a wager input device for receiving a primary wager from a player, the player associated with a player account, and at least one display for displaying a primary wagering game and a secondary wagering game. Secondary wagering game outcomes are independent of the primary wagering game. The system further comprises a controller operative to cause the at least one display to display a randomly selected outcome of the primary wagering game; upon the occurrence of a first triggering event, enter a player into the secondary wagering game, wherein the player is represented in the secondary wagering game by a player avatar; upon the occurrence of a second triggering event, end the player?s participation in the secondary wagering game; award the player any awards collected by the player avatar in the secondary wagering game; and credit the player account by the amount of the collected awards. | 12-10-2015 |
20150356833 | Wagering Game With Symbols Accrual Determining Bonus Award Upon Triggering Event - A gaming system includes a gaming cabinet, an electronic display device, one or more electronic input devices, and game-logic circuitry that initiates a casino wagering game in response to a wager input and that randomly selects a plurality of symbols arranged in an array. The array includes at least one trigger symbol and a plurality of non-trigger symbols, including first and second non-trigger symbols. In response to the trigger symbol being randomly selected, a bonus enhancement is determined based on an accrued number of the first non-trigger symbols within the array. An initial award is awarded based on an aggregated value of the second non-trigger symbols. A final award is awarded by enhancing the initial award with the bonus enhancement. | 12-10-2015 |
Ichiri Aoki, San Clemente, CA US
Patent application number | Description | Published |
---|---|---|
20120001692 | ADAPTIVE POWER AMPLIFIER - Reconfigurable distributed active transformers are provided. The exemplary embodiments provided allow changing of the effective number and configuration of the primary and secondary windings, where the distributed active transformer structures can be reconfigured dynamically to control the output power levels, allow operation at multiple frequency bands, maintain a high performance across multiple channels, and sustain desired characteristics across process, temperature and other environmental variations. Integration of the distributed active transformer power amplifiers and a low noise amplifier on a semiconductor substrate can also be provided. | 01-05-2012 |
20120176200 | CROSS-DIFFERENTIAL AMPLIFIER - A cross-differential amplifier is provided. The cross-differential amplifier includes an inductor connected to a direct current power source at a first terminal. A first and second switch, such as transistors, are connected to the inductor at a second terminal. A first and second amplifier are connected at their supply terminals to the first and second switch. The first and second switches are operated to commutate the inductor between the amplifiers so as to provide an amplified signal while limiting the ripple voltage on the inductor and thus limiting the maximum voltage imposed across the amplifiers and switches. | 07-12-2012 |
John M. Aoki, Cerritos, CA US
Patent application number | Description | Published |
---|---|---|
20100145248 | SYSTEM FOR ENRICHING A BODILY FLUID WITH A GAS HAVING AUTOMATED PRIMING CAPABILITIES - This invention discloses a modular system having a base module, a mid-section control module, and a display module for preparing and administering a gas-enriched bodily fluid. Gas-enrichment is achieved by a gas-enriching device which can be in the form of a disposable cartridge. During operation, the gas-enrichment device is placed in an enclosure within the control module to form a fluid pathway for extracorporeal circulation of the bodily fluid. An electronic controller manages the various aspects of the system and executes an automated method for priming the extracorporeal circuit. | 06-10-2010 |
20100145249 | SYSTEM FOR ENRICHING A BODILY FLUID WITH A GAS HAVING A REMOVABLE GAS-ENRICHMENT DEVICE WITH AN INFORMATION RECORDING ELEMENT - This invention discloses a modular system having a base module, a mid-section control module, and a display module for preparing and administering a gas-enriched bodily fluid via an extracorporeal circuit. Gas-enrichment is achieved by a gas-enriching device which can be in the form of a disposable cartridge. The gas-enrichment device has an information recording element disposed thereon. During operation, the gas-enrichment device is placed in an enclosure within the control module. An electronic controller manages the various aspects of the system such as the production of gas-enriched fluid, flow rates, bubble detection, and automatic operation and shut down. The controller is capable of setting a fluid flow rate in the circuit according to a programming based on the information encoded in the information recording element. | 06-10-2010 |
Kei R. Aoki, Coto De Caza, CA US
Patent application number | Description | Published |
---|---|---|
20080213796 | GFP-SNAP25 Fluorescence Release Assay for Botulinum Toxin Protease Activity - The present invention provides a nucleic acid molecule which contains a nucleotide sequence encoding a SNAP-25 substrate which includes (i) a green fluorescent protein; (ii) a first partner of an affinity couple; and (iii) a portion of SNAP-25 that includes a BoNT/A, BoNT/C1 or BoNT/E recognition sequence containing a cleavage site, where the cleavage site intervenes between the green fluorescent protein and the first partner of the affinity couple. Further provided herein is a nucleic acid molecule which contains a nucleotide sequence encoding a tagged toxin substrate which includes (i) a fluorescent protein; (ii) a first partner of an affinity couple; and (iii) a clostridial toxin recognition sequence containing a cleavage site, where the cleavage site intervenes between the fluorescent protein and the first partner of the affinity couple. | 09-04-2008 |
Kei Roger Aoki, Irvine, CA US
Patent application number | Description | Published |
---|---|---|
20090035822 | Fusion Proteins - A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent. Nucleic acid sequences encoding the polypeptide fusion proteins, methods of preparing same and uses thereof are also described. | 02-05-2009 |
20100247509 | Fusion Proteins - A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent. Nucleic acid sequences encoding the polypeptide fusion proteins, methods of preparing same and uses thereof are also described. | 09-30-2010 |
20110027256 | FUSION PROTEINS - A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a dynorphin Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the dynorphin Targeting Moiety; and a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent. Nucleic acid sequences encoding the polypeptide fusion proteins, methods of preparing same and uses thereof are also described. | 02-03-2011 |
20110091437 | FUSION PROTEINS - A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a dynorphin Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the dynorphin Targeting Moiety; and a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent. Nucleic acid sequences encoding the polypeptide fusion proteins, methods of preparing same and uses thereof are also described. | 04-21-2011 |
20110177053 | NON-CYTOTOXIC PROTEIN CONJUGATES - The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell. Nucleic acid sequences encoding the protein conjugates, methods of preparing same and uses thereof are also described. | 07-21-2011 |
20120058098 | NON-CYTOTOXIC PROTEIN CONJUGATES - The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a dynorphin Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell. Nucleic acid sequences encoding the protein conjugates, methods of preparing same and uses thereof are also described. | 03-08-2012 |
20120064059 | FUSION PROTEINS - A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent. Nucleic acids encoding the fusion proteins, methods of preparing same and uses thereof are also described. | 03-15-2012 |
20120156186 | NON-CYTOTOXIC PROTEIN CONJUGATES - The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a galanin Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell. Nucleic acid sequences encoding the protein conjugates, methods of preparing same and uses thereof are is also described. | 06-21-2012 |
20120189610 | TREATMENT OF PAIN - Use of a therapeutic molecule, for the treatment of specific pain conditions, wherein the therapeutic molecule is a single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment can cleave a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that can bind to a Binding Site on the nociceptive sensory afferent, which Binding Site can undergo endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and a translation domain that can translocate the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent. | 07-26-2012 |
20120207735 | NON-CYTOTOXIC PROTEIN CONJUGATES - The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion to apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell wherein the Targeting Moiety is selected from the group consisting of BAM, β-endorphin, bradykinin, substance P, dynorphin and/or nociceptin. | 08-16-2012 |
20120230975 | FUSION PROTEINS - A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment can cleave a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that can bind to a Binding Site on the nociceptive sensory afferent, which Binding Site can undergo endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, which is located between the non-cytotoxic protease and the Targeting Moiety; and a translocation domain that can translocate the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent; wherein the Targeting Moiety is BAM, β-endorphin, bradykinin, substance P, dynorphin and/or nociceptin. Nucleic acid sequences encoding the fusion proteins, methods of preparing same and uses thereof are also described. | 09-13-2012 |
20130189238 | FUSION PROTEINS - A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a dynorphin Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the dynorphin Targeting Moiety; and a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent. Nucleic acid sequences encoding the polypeptide fusion proteins, methods of preparing same and uses thereof are also described. | 07-25-2013 |
20130295643 | NON-CYTOTOXIC PROTEIN CONJUGATES - The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a dynorphin Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell. Nucleic acid sequences encoding the protein conjugates, methods of preparing same and uses thereof are also described. | 11-07-2013 |
20140294797 | NON-CYTOTOXIC PROTEIN CONJUGATES - The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell wherein the Targeting Moiety is selected from the group consisting of BAM, β-endorphin, bradykinin, substance P, dynorphin and/or nociceptin. | 10-02-2014 |
Kei Roger Aoki, Caza, CA US
Patent application number | Description | Published |
---|---|---|
20100055727 | FRET PROTEASE ASSAYS FOR BOTULINUM SEROTYPE A/E TOXINS - The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor. | 03-04-2010 |
Kei Roger Aoki, Garden Grove, CA US
Patent application number | Description | Published |
---|---|---|
20090317839 | BOTULINUM TOXIN SCREENING ASSAYS - Methods for detecting BoNT/A activity in a sample, methods for screening molecules able to compete with BoNT/A receptor binding, methods for reducing BoNT/A activity in a human and methods of marketing a neurotoxin capable of selectively binding to FGFR3 to a governmental or regional regulatory authority. | 12-24-2009 |
Kei Roger Aoki, Coto De Caz, CA US
Patent application number | Description | Published |
---|---|---|
20090004224 | ACTIVATABLE CLOSTRIDIAL TOXINS - Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids. | 01-01-2009 |
Koichi Aoki, San Francisco, CA US
Patent application number | Description | Published |
---|---|---|
20150135044 | INFORMATION PROCESSING APPARATUS, INFORMATION PROCESSING METHOD, COMPUTER PROGRAM, AND RECORDING MEDIUM - Disclosed herein is an information processing apparatus including: a native processing section adapted to perform processing based on a program stored therein so as to generate a native image as a processing result; a web processing section adapted to generate a web image based on data requested to a server; and a display image generation section adapted to generate a display image and output the display image to a display device, the display image including an element image making up at least part of the native image and an element image making up at least part of the web image, in which the native processing section and the web processing section move the element images in the same direction when the target to be operated by a user is switched between the native image and the web image to change the configuration of the display image. | 05-14-2015 |
K. Roger Aoki, Laguna Hills, CA US
Patent application number | Description | Published |
---|---|---|
20090318360 | Use of the neurotoxic component of a botulinum toxin for treating arthritis - A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G. | 12-24-2009 |
K. Roger Aoki, Irvine, CA US
Patent application number | Description | Published |
---|---|---|
20100034802 | TREATMENT OF PAIN - Use of a therapeutic molecule, for the treatment of specific pain conditions, wherein the therapeutic molecule is a single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent. | 02-11-2010 |
Norihiro Edwin Aoki, San Jose, CA US
Patent application number | Description | Published |
---|---|---|
20140006278 | SAVE TO OPEN WALLET | 01-02-2014 |
20140317517 | COMMERCE ORIENTED UNIFORM RESOURCE LOCATER (URL) SHORTENER - A uniform resource locator (URL) shortener relies on client-side support to embed links to websites into, for example, text messages, emails, tweets, or other forms of microblogging, and that provides additional capabilities. A method may include: recognizing a token indicator; recognizing a token in conjunction with the token indicator; selecting a template corresponding to the token indicator; and executing a process enabled according to the token and the template. Executing an enabled process may include one or more of: generating a URL; generating a URL that is itself a server-based URL shortener, in which the token indicator is substituted for the server-based URL shortener hostname to reduce the character count from that of the server-based URL shortener; displaying information from a destination website of the URL generated from the token and the template; or generating a URL according to a distinctive visual characteristic of the token indicator. | 10-23-2014 |
Norihiro Edwin Aoki, Sunnyvale, CA US
Patent application number | Description | Published |
---|---|---|
20120191553 | POINT OF SALE PAYMENT SYSTEM - A method for point of sale payments includes receiving, from a seller device over a network, payment information. The payment information is associated with payment code information in a database. The payment code information is then sent to the seller device over the network for posting at a service location. The payment code information is then captured by a payer device at the service location and transmitted over the network. The payment information is then retrieved from the database using the associated payment code information. The payment information is then sent to the payer device over the network. A payment confirmation is received from the payer device over the network and, in response, a payment from a payer account to a seller account is initiated and the payment information and an indication of the payment confirmation is sent to the seller device over the network. | 07-26-2012 |
20120246018 | POINT OF SALE PAYMENT SYSTEM - A method for point of sale payments includes receiving, from a seller device over a network, payment information. The payment information is associated with payment code information in a database. The payment code information is then sent to the seller device over the network for posting at a service location. The payment code information is then captured by a payer device at the service location and transmitted over the network. The payment information is then retrieved from the database using the associated payment code information. The payment information is then sent to the payer device over the network. A payment confirmation is received from the payer device over the network and, in response, a payment from a payer account to a seller account is initiated and the payment information and an indication of the payment confirmation is sent to the seller device over the network. | 09-27-2012 |
20130006856 | FLEXIBLE PAYMENT INSTRUMENT - Systems and methods are provided for transactions using a flexible payment instrument. A method according to an embodiment comprises allowing a giver to obtain a flexible payment instrument and specify one or more arbitrarily complex conditions for use of the flexible payment instrument on a per-payment-instrument basis in connection with one or more transactions. The method also comprises linking, by a remote location, the flexible payment instrument to an account of the giver maintained at the remote location, wherein the giver provides the flexible payment instrument to a recipient issued with the condition(s) specified by the giver for use by the recipient in connection with the one or more transactions. The method further comprises comparing, at the remote location, the condition(s) specified by the giver with transaction information details upon the use by the recipient of the flexible payment instrument in connection with the transaction(s). If the transaction information details are in compliance with the condition(s) specified by the giver, authorizing the transaction(s) using the flexible payment instrument. | 01-03-2013 |
20130080525 | SYSTEMS AND METHODS FOR TRANSFERRING APPLICATION STATE BETWEEN DEVICES BASED ON GESTURAL INPUT - Systems and methods are provided for transferring state between devices. In one implementation, a gestural input is detected, and a state of a source application is transferred from a first device to a second device in response to the gestural input. The second device may then generate an instance of a target application that corresponds to a representation of the state of the source application received from the first device. In an additional implementation, a state of the target application is transferred from the second device to the first device. The first device then updates a state of the source application to correspond to a representation of the state of the target application received from the second device. | 03-28-2013 |
Norihiro Edwin Aoki, Sunneyvale, CA US
Patent application number | Description | Published |
---|---|---|
20100199347 | Method and Apparatus for Authenticating Usage of an Application - Methods and apparatuses, including computer program products, are described for authenticating the usage of an application. A request to execute an application is received from a user device. The application is executed based on the request. An application-level usage indicator is received from the user device. The application-level usage indicator corresponds to current operation of the application by a user and comprises at least (i) user input commands and (ii) passive usage metrics. The identity of the user is determined by comparing the application-level usage indicator with a pre-established user profile wherein the user profile is associated with previous operation of the application by the user and comprises at least (i) user input commands and (ii) passive usage metrics. Execution of the application is terminated at the user device if the identified user is not entitled to use the application according to the user profile. | 08-05-2010 |
Paul M. Aoki, Berkeley, CA US
Patent application number | Description | Published |
---|---|---|
20090007236 | System And Method For Using A Communication Lease To Open A Communication Channel - A system and method for using a communication lease to open a communication channel is provided. An initiation terminal transmits a channel initiation request for access to a resource manager through a target terminal. Evaluation of a communication lease controlling access to the resource manager is awaited. Approval of the channel initiation request is received upon the successful evaluation of the communication lease. A communication channel is opened between the initiation terminal and the target terminal upon receipt of the approval. | 01-01-2009 |
20100057445 | System And Method For Automatically Adjusting Floor Controls For A Conversation - A system and method for automatically adjusting floor controls for a conversation is provided. Audio streams are received, which each originate from an audio source. Floor controls for a current configuration including at least a portion of the audio streams are maintained. Conversational characteristics shared by two or more of the audio sources are determined. Possible configurations for the audio streams are identified based on the conversational characteristics. An analysis of the current configuration and the possible configurations is performed. A change threshold is applied to the analysis. When the analysis satisfies the change threshold, the floor controls are automatically adjusted. The audio streams are mixed into one or more outputs based on the adjusted floor controls. | 03-04-2010 |
20100289730 | FOLDING ELECTRONIC DEVICE WITH CONTINUOUS DISPLAY - In general, in one aspect, the disclosure describes an apparatus that includes two panels pivotally connected together. The panels can pivot from an open arrangement where the two panels lay side by side to a closed arrangement where the two panels lay one on top of another. The apparatus also includes a flexible display connected to the two panels and having a portion that is mechanically free from the two panels. The apparatus further includes a cavity to receive at least a portion of the free portion of the display when the panels are pivoted into the closed arrangement. | 11-18-2010 |
20110018785 | SLIDE-OUT INFORMATION DISPLAY - Slide-out and roll-up information displays and methods supply enlarged viewing areas. A slide-out information display device includes stacked display segments wherein each of the display segments except one is at least partially covered by the others. Separable bezel segments support the display segments, the stacked display segments being uncovered when the bezel segments are separated from a collapsed configuration to an un-collapsed configuration for use by a user. A roll-up display device includes flexible display membranes. Scrolling assemblies in the roll-up display include rotatably mounted scrolling assembly mechanisms for rolling up the flexible display membranes. Some scrolling assemblies are movable and can be extended beyond the housing members. At least one display membrane being covered by at least one other display membrane when the movable scrolling assemblies are not extended, and the covered display membranes being uncovered when the movable scrolling assemblies are extended. | 01-27-2011 |
20110037827 | System And Method For Coordinating Data Transmission Via User-Maintained Modes - A method and apparatus for controlling data transmission via user-maintained modes is provided. A first audio data stream is recorded on a transmitting electronic apparatus. A second audio data stream is stored on the transmitting electronic apparatus. Transmission of one of the first and the second audio data streams is controlled via a first user-maintained mode when at least the other of the first and the second audio data streams is being transmitted to the electronic apparatus. The one of the first and the second audio data streams is transmitted to a receiving electronic apparatus and the other of the first and the second audio data streams is suspended. | 02-17-2011 |
20120158402 | System And Method For Adjusting Floor Controls Based On Conversational Characteristics Of Participants - A system and method for automatically adjusting floor controls based on conversational characteristics is provided. Audio streams are received, which each originate from an audio source. Floor controls for a current configuration including at least a portion of the audio streams are maintained. Conversational characteristics shared by two or more of the audio sources are determined. Possible configurations for the audio streams are identified based on the conversational characteristics. An analysis of the current configuration and the possible configurations is performed. A change threshold comprising a minimum number of timeslices for at least one of the current configuration and one of the possible configurations is applied to the analysis. When the analysis satisfies the change threshold, the floor controls are automatically adjusted. The audio streams are mixed into one or more outputs based on the adjusted floor controls. | 06-21-2012 |
20120162049 | FOLDING ELECTRONIC DEVICEWITH CONTINUOUS DISPLAY - In general, in one aspect, the disclosure describes an apparatus that includes two panels pivotally connected together. The panels can pivot from an open arrangement where the two panels lay side by side to a closed arrangement where the two panels lay one on top of another. The apparatus also includes a flexible display connected to the two panels and having a portion that is mechanically free from the two panels. The apparatus further includes a cavity to receive at least a portion of the free portion of the display when the panels are pivoted into the closed arrangement. | 06-28-2012 |
20130204616 | Computer-Implemented System and Method for Enhancing Audio to Individuals Participating in a Conversation - A computer-implemented system and method for enhancing audio to individuals participating in a conversation is provided. Audio data for individuals participating in one or more conversations is analyzed. Possible conversational configurations of the individuals are generated based on the audio data, and each possible conversational configuration includes one or more subconfigurations of at least two of the individuals. A probability weight is assigned to each of the subconfigurations and includes a likelihood that the individuals of that subconfiguration are participating in one of the conversations. A probability of each possible conversational configuration is determined by combining the probability weights for the subconfigurations of that possible conversational configuration. The possible conversational configuration with the highest probability is selected as a most probable configuration. The individuals participating in the conversations are determined based on the most probable configuration. Audio for each individual participating in the determined conversations is enhanced. | 08-08-2013 |
20140046665 | Computer-Implemented System And Method For Enhancing Visual Representation To Individuals Participating In A Conversation - A system and method for enhancing visual representation to individuals participating in a conversation is provided. Visual data for a plurality of individuals participating in one or more conversations is analyzed. Possible conversational configurations of the individuals are generated. Each possible conversational configuration includes one or more pair-wise probabilities of at least two of the individuals. A probability weight is assigned to each of the pair-wise probabilities having a likelihood that the individuals of that pair-wise probability are participating in a conversation. A probability of each possible conversational configuration is determined by combining the probability weights for the pair-wise probabilities of that possible conversational configuration. The possible conversational configuration with the highest probability is selected as a most probable configuration. The individuals participating in the conversations based on the pair-wise probabilities with the most probable configuration are determined. Visual representation is enhanced for each individual participating in the determined conversations. | 02-13-2014 |
Paul Masami Aoki, Berkeley, CA US
Patent application number | Description | Published |
---|---|---|
20090313553 | System And Method For Providing Multimedia Content Between A Plurality Of User Terminals - A system and method for providing multimedia content between a plurality of user terminals is presented. A first multimedia presentation on a first user terminal is selected by a first user. Data corresponding to the first multimedia presentation is transmitted to a second user terminal. Data is received corresponding to a second multimedia presentation from the second user terminal by the first user terminal. The first multimedia presentation or the second multimedia presentation is displayed on the first user terminal and the second user terminal based on, respectively, a first profile of the first user terminal and a second profile of the second user terminal. | 12-17-2009 |
Rober K. Aoki, Coto De Caza, CA US
Patent application number | Description | Published |
---|---|---|
20140302007 | BOTULINUM TOXIN FORMULATION - neurotoxin formulated with a hyaluronic acid carrier with increased residency time of the | 10-09-2014 |
Roger K. Aoki, Irvine, CA US
Patent application number | Description | Published |
---|---|---|
20090162341 | Non-Cytotoxic Protein Conjugates - A non-cytotoxic protein conjugate for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell, comprising: (i) a Targeting Moiety (TM), wherein said TM is an agonist of a receptor present on said nociceptive sensory afferent cell, and wherein said receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of said nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell. Nucleic acid sequences encoding the protein conjugates, methods of preparing same and uses thereof are also described. | 06-25-2009 |
Roger K. Aoki, Coto De Caza, CA US
Patent application number | Description | Published |
---|---|---|
20120141532 | Botulinum Toxin Formulation - Botulinum neurotoxin formulated with a hyaluronic acid carrier with increased residency time of the botulinum toxin at a subdermal location and fewer botulinum toxin induced complications or side effects. | 06-07-2012 |
Roger Kei Aoki, Irvine, CA US
Patent application number | Description | Published |
---|---|---|
20150197739 | FUSION PROTEINS AND METHODS FOR TREATING, PREVENTING OR AMELIORATIONG PAIN - A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, which protease is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a galanin Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease and the galanin Targeting Moiety; a translocation domain that is capable of translocating the protease from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent; a first spacer located between the non-cytotoxic protease and the protease cleavage site, wherein said first spacer comprises an amino acid sequence of from 4 to 25 amino acid residues; and a second spacer located between the galanin Targeting Moiety and the translocation domain, wherein said second spacer comprises an amino acid sequence of from 4 to 35 amino acid residues. Nucleic acid sequences encoding the polypeptide fusion proteins, methods of preparing same and uses thereof are also described. | 07-16-2015 |
Stephanie Aoki, Goleta, CA US
Patent application number | Description | Published |
---|---|---|
20080317762 | Bacterial Contact Inhibition and Methods Therefor - Contemplated compositions and methods relate to bacterial contact inhibition that is conferred by two gene products, CdiA and CdiB, which are encoded by the genes cdiA and cdiB, respectively. A further gene product CdiI, encoded by the gene cdiI confers immunity to contact inhibition caused by CdiAB. | 12-25-2008 |
Thomas T. Aoki, Sacramento, CA US
Patent application number | Description | Published |
---|---|---|
20140046020 | PRE-OPERATIVE USE OF METABOLIC ACTIVATION THERAPY - Metabolic Activation Therapy (MAT®) is a procedure which uses intravenous insulin pulses administered with oral glucose to deliver an insulin treatment regimen that improves the biochemistry and physiology of diabetic and non-diabetic individuals. If implemented preoperatively to patients with a history of hyperglycemia who undergo surgical and other stress inducing procedures, including those requiring hospitalization, postoperative glycemic control is improved and the insulin required during and after the operation is decreased with no increase in incidents of hypoglycemia. If implemented in patients not previously known to have diabetes but who are at high risk for becoming hyperglycemic in response to said surgical/medical procedures known to be physiologically stressful, it results in increased insulin sensitivity, lower circulating glucose levels post procedure, and shorter length of hospital stay. At the attending physician's discretion, patients already receiving MAT® treatment on a weekly or bi-weekly basis may not require any additional treatment prior to undergoing surgical or other stress inducing medical procedures. | 02-13-2014 |